Gut Microbiome and Treatment Response in Autoimmune Hepatitis: A Review of Mechanisms and Clinical Evidence

Authors

  • Mohammad Karami Horestani Assistant Professor of Gastroenterology and Hepatology. Department of Internal Medicine, Clinical Research Development Unit, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord. Author

Keywords:

Autoimmune hepatitis, Gut microbiome, Dysbiosis, Treatment response, Gut-liver axis

Abstract

Autoimmune hepatitis is a chronic immune-mediated liver disease in which treatment response varies substantially among patients. Increasing evidence indicates that gut microbiome dysbiosis may influence disease activity and therapeutic response through the gut-liver axis. This review examines the mechanisms linking microbial alterations with treatment response, focusing on intestinal barrier dysfunction, microbial metabolites, T-cell regulation, and inflammatory signaling. Available evidence suggests that dysbiosis may increase intestinal permeability, facilitate microbial translocation, and promote hepatic inflammation. Microbiome-derived metabolites may also regulate immune tolerance and inflammatory responses through interactions with immune signaling pathways. Experimental studies indicate that modulation of the gut microbiome can alter autoimmune hepatic inflammation and may modify responses to immunosuppressive treatment. However, clinical evidence in humans remains limited and heterogeneous, and differences in microbiome composition, treatment exposure, and study methodology complicate direct comparisons. Current evidence therefore supports the gut microbiome as a promising mechanistic and translational target, but not yet as an established biomarker for treatment selection or response prediction. Future longitudinal clinical studies integrating microbiome profiles, microbial metabolites, immune parameters, and standardized treatment outcomes are needed to determine its potential role in personalized management of autoimmune hepatitis.

References

Liu Q, Tian H, Kang Y, Tian Y, Li L, Kang X, et al. Probiotics alleviate autoimmune hepatitis in mice through modulation of gut microbiota and intestinal permeability. J Nutr Biochem. 2021;98:108863.

Ma L, Zhang L, Zhuang Y, Ding Y, Chen J. Lactobacillus improves the effects of prednisone on autoimmune hepatitis via gut microbiota-mediated follicular helper T cells. Cell Commun Signal. 2022;20(1):83.

Centa M, Weinstein EG, Clemente JC, Faith JJ, Fiel MI, Lyallpuri R, et al. Impaired central tolerance induces changes in the gut microbiota that exacerbate autoimmune hepatitis. J Autoimmun. 2022;128:102808.

Pandey SP, Bender MJ, McPherson AC, Phelps CM, Medina Sanchez L, Rana M, et al. Tet2 deficiency drives liver microbiome dysbiosis triggering Tc1 cell autoimmune hepatitis. Cell Host Microbe. 2022;30(7):1003-1019.e10.

Kang Y, Kuang X, Yan H, Ren P, Yang X, Liu H, et al. A novel synbiotic alleviates autoimmune hepatitis by modulating the gut microbiota-liver axis and inhibiting the hepatic TLR4/NF-κB/NLRP3 signaling pathway. mSystems. 2023;8(2):e01127-22.

Lin H, Lin J, Pan T, Li T, Jiang H, Fang Y, et al. Polymeric immunoglobulin receptor deficiency exacerbates autoimmune hepatitis by inducing intestinal dysbiosis and barrier dysfunction. Cell Death Dis. 2023;14(1):68.

Li L, Kang Y. The gut microbiome and autoimmune hepatitis: implications for early diagnostic biomarkers and novel therapies. Mol Nutr Food Res. 2023;67(24):e2300043.

Sun C, Zhu D, Zhu Q, He Z, Lou Y, Chen D. The significance of gut microbiota in the etiology of autoimmune hepatitis: a narrative review. Front Cell Infect Microbiol. 2024;14:1337223.

Yang H, Liu Q, Liu H, Kang X, Tian H, Kang Y, et al. Berberine alleviates concanavalin A-induced autoimmune hepatitis in mice by modulating the gut microbiota. Hepatol Commun. 2024;8(4):e0381.

Wu Q, Ge Z, Lv C, He Q. Interacting roles of gut microbiota and T cells in the development of autoimmune hepatitis. Front Immunol. 2025;16:1584001.

Zhang X, Wan L, Zheng Y, Ai Y. Gut barrier, microbial metabolites, and immune homeostasis in autoimmune hepatitis: from molecular mechanisms to strategies. Front Biosci (Landmark Ed). 2025;30(5):27747.

Li B, Liang X, Li Y, Wang R, Wei Y, Liu Q, et al. Tryptophan catabolites from microbiota ameliorate immune-mediated hepatitis through activating aryl hydrocarbon receptor of T cells. Gut Microbes. 2025;17(1):2557979.

Iftikhar F, Iftikhar A, Khalid M, Talha M, Waafira A. Gut microbial signatures in autoimmune hepatitis: unlocking diagnostic and therapeutic potential. Ann Med Surg (Lond). 2025;87(10):6868-6869.

Downloads

Published

2024-12-22

Issue

Section

Research article

How to Cite

Gut Microbiome and Treatment Response in Autoimmune Hepatitis: A Review of Mechanisms and Clinical Evidence. (2024). Scientific Journal of Research Studies in Future Basic Sciences and Medical Sciences, 2(1), 84-97. https://journalhi.com/sci/article/view/467

Most read articles by the same author(s)

Similar Articles

1-10 of 19

You may also start an advanced similarity search for this article.